[Correspondence]The Ratio of Peripheral Regulatory T Cells to Lox-1+ Polymorphonuclear Myeloid-derived Suppressor Cells Predicts the Early Response to Anti–PD-1 Therapy in Patients with Non–Small Cell Lung Cancer
 Authors and Affiliations
 Authors and Affiliations
Hye Ryun Kim1*¢Ô , Su-Myeong Park2*, Sang-Uk Seo2,3, Inkyung Jung1, Hong In Yoon1, Dmitry I. Gabrilovich4, Byoung Chul Cho1,5¢Ô, Seung-Yong Seong2,3¢Ô, Sang-Jun Ha6¢Ô , and Je-In Youn 2,3,6¢Ô¡×
1 Yonsei University College of Medicine Seoul, Korea 2 Seoul National University College of Medicine Seoul, Korea 3 Seoul National University College of Medicine Hongcheon, Korea 4 Wistar Institute Philadelphia, Pennsylvania 5 JEUK Co., Ltd. Gumi City, Korea and 6 Yonsei University Seoul, Korea
*These authors contributed equally to this work. ¢ÔJoint principal investigators who contributed equally to this study. ¡×Corresponding author
Abstract Immune checkpoint inhibitors (ICIs) have emerged as a promising treatment modality for patients with non-small cell lung cancer (NSCLC). However, ICI monotherapy has a relatively low response rate (approximately 20-50% in patients with NSCLC) (1), and consequently it is important to develop predictive biomarkers of response to inform clinical decisions regarding ICI use. Although PD-L1 expression on tumor cells is currently used as a predictive determinant for anti-PD-1 therapy responses, the accuracy of this test is relatively poor. Therefore, better predictive biomarkers for anti-PD-1 therapy in patients with NSCLC are needed.
|